Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-137244

Published: 2020

Journal Articles

Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136064

Published: 2020

Journal Articles

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141774

Published: 2020

Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-142659

Published: 2020

Journal Articles

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Quy Le, PhD, Thao T. Tang, Darcy Hamill, DO, Anilkumar Gopalakrishnapillai, PhD, Sonali Barwe, PhD MSc, Rhonda E. Ries, MA, Richard Aplenc, MD PhD, Andrew C. Wood, MD, E. Anders Kolb, MD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134821

Published: 2020

Journal Articles

Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia

Benjamin J. Huang, MD, Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Erin Lynn Crowgey, PhD, Scott N. Furlan, MD, Timothy Shaw, PhD, Lisa Wei, BS, Yi-Cheng Wang, MS, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Todd M. Cooper, DO, Edward A. Kolb, MD, Xiaotu Ma, PhD, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142638

Published: 2020

Journal Articles

Distinct Co-Occurring Mutational Profiles in Acute Myeloid Leukemia Confers Prognostic Significance in Children and Young Adults with FLT3 /ITD Mutations

Katherine Tarlock, MD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Rhonda E. Ries, MA, Brenda Gibson, MD PhD, Naghmeh Niktoreh, Sanne Noort, MD MSc, Marry M. Van den Heuvel-Eibrink, MD, C. Michel Zwaan, MD PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 443.

https://doi.org/10.1182/blood-2018-99-113676

Published: 2018

Journal Articles

Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML

Padmini Narayanan, PhD, Yi-Cheng Wang, Chris Tsz-Kwong Man, PhD, Rhonda E. Ries, MA, Robert B Gerbing, MA, Soheil Meshinchi, MD PhD, Todd A Alonzo, PhD, Michele Redell, MD PhD

Blood (2018) 132 (Supplement 1): 1510.

https://doi.org/10.1182/blood-2018-99-118771

Published: 2018

Journal Articles

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Marianne T. Santaguida, BSc, PhD, Christos Gekas, PhD, Todd A Alonzo, PhD, Robert B Gerbing, MA, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Tiffany Hylkema, BS, Lisa Eidenschink Brodersen, PhD, Michael R. Loken, PhD, Hamid Bolouri, PhD, Soheil Meshinchi, MD PhD

Blood (2018) 132 (Supplement 1): 881.

https://doi.org/10.1182/blood-2018-99-115544

Published: 2018

Journal Articles

Quality of Life in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Rajaram Nagarajan, MD MS, Todd A Alonzo, PhD, Robert B Gerbing, MA, Donna Johnston, MD FRCPC, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD, Lamia Barakat, PhD, Lillian Sung, MD PhD

Blood (2018) 132 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2018-99-112152

Published: 2018

Journal Articles

Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group

Todd M Cooper, DO, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 2794.

https://doi.org/10.1182/blood.V128.22.2794.2794

Published: 2016

Journal Articles

The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group

Donna L Johnston, MD FRCPC, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Richard Aplenc, MD PhD, William G Woods, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 4016.

https://doi.org/10.1182/blood.V128.22.4016.4016

Published: 2016

Journal Articles

Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

Andrew P. Voigt, Lisa Eidenschink Brodersen, PhD, Robert B. Gerbing, MA, Andrew J. Menssen, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2015) 126 (23): 1377.

https://doi.org/10.1182/blood.V126.23.1377.1377

Published: 2015

Journal Articles

ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative

Jason E. Farrar, MD, Todd A. Alonzo, PhD, Rhonda E. Ries, MA, Robert B. Gerbing, MA, Jaime M. Guidry Auvil, PhD, Tanja M. Davidsen, PhD, Patee Gesuwan, Leandro C. Hermida, Marco A Marra, PhD, Andrew J. Mungall, PhD, Karen Mungall, PhD, Yussanne Ma, PhD, William Long, PhD, Stuart Zong, E. Anders Kolb, MD, Malcolm A. Smith, MD PhD, Daniela S. Gerhard, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 2587.

https://doi.org/10.1182/blood.V126.23.2587.2587

Published: 2015

Journal Articles

High Expression of Myocyte Enhancer Factor 2C ( MEF2C ) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

George S. Laszlo, PhD, Todd A. Alonzo, PhD, Chelsea J. Gudgeon, BS, Kimberly H. Harrington, BS, Alex Kentsis, MD PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2570.

https://doi.org/10.1182/blood.V126.23.2570.2570

Published: 2015

Journal Articles

Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Cecilia Fu, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, James H. Feusner, MD, John Gregory, Jr., MD

Blood (2015) 126 (23): 219.

https://doi.org/10.1182/blood.V126.23.219.219

Published: 2015

Journal Articles

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Lillian Sung, MD PhD, Richard Aplenc, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 800.

https://doi.org/10.1182/blood.V126.23.800.800

Published: 2015

Journal Articles

A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531

Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Andrew J. Menssen, Robert B. Gerbing, MA, Laura Pardo, Andrew P. Voigt, Samir B. Kahwash, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2015) 126 (23): 560.

https://doi.org/10.1182/blood.V126.23.560.560

Published: 2015

Journal Articles

Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106

Fabiana Ostronoff, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Matthew A. Kutny, MD, Robert B. Gerbing, MA, Jerald P. Radich, MD, Harry P Erba, MD PhD, Frederick R. Appelbaum, MD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Derek L. Stirewalt, MD, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 2576.

https://doi.org/10.1182/blood.V126.23.2576.2576

Published: 2015

Journal Articles

Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative

Blood (2015) 126 (23): 170.

https://doi.org/10.1182/blood.V126.23.170.170

Published: 2015

NARROW

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia

Distinct Co-Occurring Mutational Profiles in Acute Myeloid Leukemia Confers Prognostic Significance in Children and Young Adults with FLT3 /ITD Mutations

Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

Quality of Life in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group

The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group

Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531

ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative

High Expression of Myocyte Enhancer Factor 2C ( MEF2C ) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531

Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106

Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only